EFTR Overview

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Wall Street analysts forecast EFTR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EFTR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

eFFECTOR Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

eFFECTOR Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00

eFFECTOR Therapeutics Inc (EFTR) has 14 emplpoyees as of April 21 2026.

Today EFTR has the market capitalization of 1.46M USD.